Gonorrhea

Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress

Retrieved on: 
Mercoledì, Maggio 8, 2024
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, Nursing care plan, Investment, IST, Ceftriaxone, New Drug Application, ESCMID, Armata, Acinetobacter, Zoliflodacin, Conference, CNS, Azithromycin, Exercise, Sulbactam, GSK, Patient, Bank, Infection, Gonorrhea, Share repurchase, Growth, Pharmaceutical industry

“Our first quarter financial results continue to demonstrate the successful transformation for Innoviva.

Key Points: 
  • “Our first quarter financial results continue to demonstrate the successful transformation for Innoviva.
  • We are pleased with our first quarter performance, led by the strong launch of our novel therapeutic XACDURO®.
  • Share repurchases: During the first quarter 2024, Innoviva repurchased 0.6 million shares of its outstanding common stock for $9.7 million.
  • In the first quarter 2024, Innoviva invested an additional $35.0 million in one of our assets, Armata, to help advance its lead therapeutic phage candidates.

Testmate Health Raises $6M In Seed Funding For First Low-Cost, At-Home STI Diagnostic Test

Retrieved on: 
Mercoledì, Maggio 8, 2024
USD, World Health Organization, Pregnancy, Infertility, OTC, Health, Helm, Research, STI, DNA, Chlamydia, Privacy, Infection, Gonorrhea, Chronic pain, Birth control

Current tests for these most commonly reported notifiable infections in the United States require in-clinic office visits and results can take days.

Key Points: 
  • Current tests for these most commonly reported notifiable infections in the United States require in-clinic office visits and results can take days.
  • Testmate Health's simple urine test is designed to provide lab-quality results at home in under 30 minutes.
  • Her research at the World Health Organization emphasized the absence of cheap and accurate STI tests, leading her to develop Testmate's revolutionary urine-based DNA platform detection technology.
  • Testmate's proprietary STI self-test will be the first to make at-home STI testing as ubiquitous as an at-home pregnancy test.

Innoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024

Retrieved on: 
Mercoledì, Aprile 24, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Neisseria gonorrhoeae, Gonorrhea, Randomized controlled trial, World Health Organization, Safety, Woman, ToC, Heart, Ceftriaxone, AMR, ESCMID, Partnership, Zoliflodacin, Azithromycin, Patient, Physician, IM, Failure, HIV, Infection, Clinical trial, Therapy, Organization, Prevalence, Cohort (statistics), Pharmaceutical industry

Zoliflodacin is a first-in-class spiropyrimidinetrione, single dose, oral antibiotic that is being developed in partnership with GARDP for the treatment of uncomplicated gonorrhea.

Key Points: 
  • Zoliflodacin is a first-in-class spiropyrimidinetrione, single dose, oral antibiotic that is being developed in partnership with GARDP for the treatment of uncomplicated gonorrhea.
  • GARDP and Innoviva Specialty Therapeutics plan to submit the Phase 3 zoliflodacin data for future publication in a medical journal.
  • Oral zoliflodacin 3g was generally well tolerated and emergent adverse events were comparable between treatment arms (46.2% vs 46.4%).
  • Details for the ESCMID Global 2024 presentations are as follows:
    Title: Oral zoliflodacin is non-inferior to a combination of ceftriaxone and azithromycin for treatment of uncomplicated urogenital gonorrhoea: results of a large global Phase 3 randomized controlled trial
    Session: 05.

MISTR, Known for its Free Online PrEP and Long-Term HIV Care, is Now Prescribing DoxyPEP

Retrieved on: 
Martedì, Aprile 16, 2024
Telemedicine, Virtual Medicine, Other Health, Pharmaceutical, Other Consumer, General Health, Philanthropy, Women, Infectious Diseases, Men, LGBTQ+, Other Philanthropy, AIDS, Lifestyle, Consumer, Health, Telehealth, Syphilis, NIH, Post-exposure prophylaxis, STI, ART, Patient, Chlamydia, Doxycycline, HIV, Gonorrhea, Pharmaceutical industry

MISTR, the largest telemedicine provider offering free online PrEP and long-term HIV care in all 50 states, D.C., and Puerto Rico, is now prescribing Doxycycline Post-Exposure Prophylaxis (DoxyPEP), an antibiotic that reduces bacterial STIs, including gonorrhea, chlamydia, and syphilis.

Key Points: 
  • MISTR, the largest telemedicine provider offering free online PrEP and long-term HIV care in all 50 states, D.C., and Puerto Rico, is now prescribing Doxycycline Post-Exposure Prophylaxis (DoxyPEP), an antibiotic that reduces bacterial STIs, including gonorrhea, chlamydia, and syphilis.
  • Beginning today, patients can now use MISTR’s seamless telehealth platform to receive DoxyPEP online for free.
  • “I’m proud that MISTR is democratizing access to PrEP, HIV Care, and now DoxyPEP.”
    DoxyPEP has already shown promising results in reducing the rates of certain STIs.
  • Now MISTR patients can receive DoxyPEP, in addition to their PrEP or HIV care medications.

SCOUT RECEIVES FUNDING FROM CARB-X TO DEVELOP A LOW-COST POINT-OF-CARE AND HOME DIAGNOSTIC FOR GONORRHEA AND CHLAMYDIA

Retrieved on: 
Giovedì, Aprile 18, 2024
Chlamydia trachomatis, FDA, Mortality, Administration, Pelvic inflammatory disease, Malaria, Death, Doctor of Philosophy, Vaccine, Development, Point-of-care testing, PHAC, Diagnosis, Gonorrhea, Novo Nordisk Foundation, Prevalence, HHS, Vertical loop, Neonatal sepsis, Infertility, OTC, Public Health Agency, Entrepreneurship, Infection, Urine, Neisseria gonorrhoeae, Patient, Ng, CARB-X, NIH, Education, BMBF, STI, Therapy, Disease, Bangladesh Technical Education Board, SARS-CoV-2, HIV/AIDS, Social work, NIAID, Bill, Physician

BOSTON, April 18, 2024 /PRNewswire/ -- Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) will award up to US$1 million to diagnostics and health tech company Scout to demonstrate proof-of-concept and feasibility ahead of development of a new point-of-care test – STI Scout. The test will detect and differentiate between Neisseria gonorrhoeae (Ng) and Chlamydia trachomatis (Ct). STI Scout is quick and inexpensive, with a turnaround time of 30 minutes and costs anticipated to be less than half of other options.

Key Points: 
  • STI Scout is quick and inexpensive, with a turnaround time of 30 minutes and costs anticipated to be less than half of other options.
  • Additionally, STI Scout can use either first void urine or vaginal swabs, and future tests will be able to guide therapy for gonorrhea treatment based on antibiotic susceptibility.
  • STI Scout uses the Scout Hub to run and the Scout Connect mobile app, which provides instructions, tracks results, and eventually will allow patients to connect digitally to a healthcare provider.
  • Scout's diagnostic is the second diagnostic and ninth project to receive a CARB-X award as part of the 2022-2023 funding call .

Recce Pharmaceuticals Granted New Patent in Israel for RECCE® Anti-Infectives

Retrieved on: 
Giovedì, Aprile 4, 2024
Escherichia coli, Central Bureau, Statistics, Burn, PCT, Shingles, Biotechnology, Growth, Disease, HIV, Klebsiella pneumoniae, COVID-19, Inhalation, HCMV, ASX, RCE, Recce, Viral, Pseudomonas aeruginosa, Virus, EBV, SARS-CoV-2, Staphylococcus aureus, Gonorrhea, Cytomegalovirus, Ross River virus, Neisseria meningitidis, GDP, Urinary tract infection, Skin, Streptococcus pyogenes, Patent, Staphylococcus, Streptococcus pneumoniae, Simplex, Infection, USD, Administration, Biology, Ageing, Pharmaceutical industry

SYDNEY, Australia, April 04, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced that the State of Israel Patent Office has formally granted Recce a new family four patent (patent number: 295116), “Process for Preparation of Biologically Active Copolymer Comprising an Acrolein Derivative and a Polyalkylene Glycol Oligomer,” with expiry in 2041.

Key Points: 
  • SYDNEY, Australia, April 04, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced that the State of Israel Patent Office has formally granted Recce a new family four patent (patent number: 295116), “Process for Preparation of Biologically Active Copolymer Comprising an Acrolein Derivative and a Polyalkylene Glycol Oligomer,” with expiry in 2041.
  • “We are thrilled to have received this newly granted patent in Israel,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
  • Israel’s pharmaceuticals and biotechnology market has a reputation for high R&D spending and an impressive international reach, with world-class export numbers and a growing market value.
  • Other examples include influenza A, Ross River virus, and coronaviruses, including those responsible for severe acute respiratory syndrome and SARS-CoV-2 (COVID-19).

Coachella Concerned That People Have Sex, Says AHF

Retrieved on: 
Giovedì, Marzo 28, 2024
Entertainment, AIDS, Health, Infectious Diseases, Music, Events, Concerts, AIDS Healthcare Foundation, STD, Condom, Syphilis, URL, Sand, Coachella (festival), United, STI, Gonorrhea, CDC, Chlamydia, AHF, Multimedia, Advertising, Pharmaceutical industry

(Photo: Business Wire)

Key Points: 
  • (Photo: Business Wire)
    The Coachella-themed billboard went up Tuesday, March 26, 2024 and will remain up throughout April as Coachella spans two weekends: April 12-14 and April 19-21.
  • Do they really not know how people spend their time during festival weekends?” said Michael Weinstein, AHF president and cofounder.
  • California ranks 22 in reported cases of chlamydia, 18th in reported cases of gonorrhea, and 19th in cases of syphilis.
  • To learn more about AHF, visit us online at AIDShealth.org , find us on Facebook , follow us on Instagram , Twitter , and TikTok , and subscribe to our AHFter Hours podcast.

Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress

Retrieved on: 
Giovedì, Marzo 7, 2024
COVID-19, Research, Infectious Diseases, FDA, Biotechnology, Health, Pharmaceutical, General Health, Science, Pfizer–BioNTech COVID-19 vaccine, Liver, European Commission, Ministry, Arcturus Therapeutics, Messenger, Ornithine transcarbamylase deficiency, Investment, Omicron, OTC, Lyme disease, CSL, MHLW, The Lancet, Vaccine, Gonorrhea, Observation, RNA, Civil service commission, Collaboration, Therapy, COVID, Ministry of Health, Patient, Valence (chemistry), Janssen, Immunity, Orphan, ARCT, Travel, Infection

“I am excited about the continued pipeline progress and efforts toward commercialization achieved by Arcturus in 2023,” said Joseph Payne, President & CEO of Arcturus Therapeutics.

Key Points: 
  • “I am excited about the continued pipeline progress and efforts toward commercialization achieved by Arcturus in 2023,” said Joseph Payne, President & CEO of Arcturus Therapeutics.
  • This marks the first marketing approval milestone for CSL and Arcturus since signing the Collaboration and License agreement in November 2022.
  • In November 2023, Arcturus received Orphan Drug Designation from the U.S. FDA for ARCT-032, for the treatment of Cystic Fibrosis.
  • We have achieved a total of approximately $396.0 million in upfront payments and milestones from CSL as of December 31, 2023.

Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress

Retrieved on: 
Giovedì, Febbraio 29, 2024
Health, Sports, Infectious Diseases, Hospitals, Clinical Trials, Pharmaceutical, Biotechnology, Therapy, New Drug Application, IST, Investment, FDA, Food, Growth, Exercise, The Lancet, Nursing care plan, CNS, Acinetobacter, Patient, Sulbactam, Infection, Gonorrhea, Pharmaceutical industry

Pavel Raifeld, Chief Executive Officer of Innoviva, said: “2023 was a successful and transformational year for Innoviva.

Key Points: 
  • Pavel Raifeld, Chief Executive Officer of Innoviva, said: “2023 was a successful and transformational year for Innoviva.
  • Share repurchase: During the fourth quarter 2023, Innoviva repurchased 1,121,835 shares of its outstanding common stock for $15.4 million.
  • Our portfolio of strategic assets under the Company’s various subsidiaries was valued at $561.0 million as of December 31, 2023.
  • In fourth quarter 2023, Innoviva invested an additional $5.0 million in one of our assets, Gate Neurosciences, to support its strategy of developing next generation targeted CNS therapies.

Sexual Health Pioneer, VerifiedMD, Introduces First STD Verification Badge

Retrieved on: 
Martedì, Marzo 5, 2024
Infection, Gonorrhea, STD, Syphilis, Partner (business rank), HIV, Risk, Partnership

NEW YORK, March 5, 2024 /PRNewswire/ -- VerifiedMD, a leading innovator in sexual health services, has launched the industry's first verification badge. The VerifiedMD badge empowers individuals to take ownership of their sexual health through a discreet, yet tangible symbol to show they are within normal limits on the day of STD testing.

Key Points: 
  • NEW YORK, March 5, 2024 /PRNewswire/ -- VerifiedMD , a leading innovator in sexual health services, has launched the industry's first verification badge.
  • The VerifiedMD badge empowers individuals to take ownership of their sexual health through a discreet, yet tangible symbol to show they are within normal limits on the day of STD testing.
  • To be eligible for the VerifiedMD badge, VerifiedMD provides a one-of-a-kind concierge testing service that allows for convenient, professional testing of six common STDs.
  • The VerifiedMD badge enables transparent confirmation of sexual health status without the associated emotions.